December 6, 2011
Bristol-Myers Squibb Co. and Johnson & Johnson said Friday they will work together to develop experimental treatments for hepatitis C virus. BMS said its drugs daclatasir (BMS-790052) and its NS5A replication complex inhibitor will be tested in combination with the NS3 protease inhibitor (TMC435) under development by J&J's Tibotec unit. Beginning in the first half of 2012, the medicines, which seek to block different proteins than those usually targeted by HCV treatments, will be tested in various combinations among patients with genotype 1, the most common and hard-to-treat HCV strain. Several companies are working to develop HCV treatments that do not include interferon, whose flu-like side effects cause many patients to avoid or discontinue treatment.
12.02.2011; Ransdell Pierson; Bill Berkrot
No comments have been made.
|This Week in HIV Research: Antibody Being Tested for HIV Prevention, and Differing Results on HCV Treatment in Coinfection|
|Which Hepatitis C Treatment to Start in 2016|
|What's the Most Overlooked Issue in HIV Care Today?|
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: When New Meets Old|